{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:23:43Z","timestamp":1791901423498,"version":"4.3.4"},"reference-count":50,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thrombolysis with tissue-type plasminogen activator (tPA) remains the main treatment for acute ischemic stroke. Nevertheless, tPA intervention is limited by a short therapeutic window, low recanalization rates, and a risk of intracranial hemorrhage (ICH), highlighting the clinical demand for improved thrombolytic drugs. We examined a novel thrombolytic agent termed \u201cSCE5-scuPA,\u201d comprising a single-chain urokinase plasminogen activator (scuPA) fused with a single-chain antibody (SCE5) that targets the activated glycoprotein IIb\/IIIa platelet receptor, for its effects in experimental stroke. SCE5-scuPA was first tested in a whole blood clot degradation assay to show the benefit of platelet-targeted thrombolysis. The tail bleeding time, blood clearance, and biodistribution were then determined to inform the use of SCE5-scuPA in mouse models of photothrombotic stroke and middle cerebral artery occlusion against tenecteplase. The impacts of SCE5-scuPA on motor function, ICH, blood\u2013brain barrier (BBB) integrity, and immunosuppression were evaluated. Infarct size was measured by computed tomography imaging and magnetic resonance imaging. SCE5-scuPA enhanced clot degradation ex\u00a0vivo compared with its nonplatelet-targeting control. The maximal SCE5-scuPA dose that maintained hemostasis and a rapid blood clearance was determined. SCE5-scuPA administration both before and 2 hours after photothrombotic stroke reduced the infarct volume. SCE5-scuPA also improved neurologic deficit, decreased intracerebral blood deposits, preserved the BBB, and alleviated immunosuppression poststroke. In middle cerebral artery occlusion, SCE5-scuPA did not worsen stroke outcomes or cause ICH, and it protected the BBB. Our findings support the ongoing development of platelet-targeted thrombolysis with SCE5-scuPA as a novel emergency treatment for acute ischemic stroke with a promising safety profile.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006691","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T06:01:55Z","timestamp":1651212115000},"page":"561-574","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Platelet-targeted thrombolysis for treatment of acute ischemic stroke"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5731-1246","authenticated-orcid":false,"given":"Jason S.","family":"Palazzolo","sequence":"first","affiliation":[{"name":"1NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anukreity","family":"Ale","sequence":"additional","affiliation":[{"name":"1NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Ho","sequence":"additional","affiliation":[{"name":"2Molecular Neurotrauma and Haemostasis, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Jagdale","sequence":"additional","affiliation":[{"name":"1NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad R. S.","family":"Broughton","sequence":"additional","affiliation":[{"name":"3Department of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-3892","authenticated-orcid":false,"given":"Robert L.","family":"Medcalf","sequence":"additional","affiliation":[{"name":"2Molecular Neurotrauma and Haemostasis, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-8651","authenticated-orcid":false,"given":"David K.","family":"Wright","sequence":"additional","affiliation":[{"name":"4Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6252-1931","authenticated-orcid":false,"given":"Karen","family":"Alt","sequence":"additional","affiliation":[{"name":"5NanoTheranostics Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7114-4023","authenticated-orcid":false,"given":"Christoph E.","family":"Hagemeyer","sequence":"additional","affiliation":[{"name":"1NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6714-9131","authenticated-orcid":false,"given":"Be\u2019eri","family":"Niego","sequence":"additional","affiliation":[{"name":"1NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"9","key":"2023081515544560800_bib1","doi-asserted-by":"crossref","DOI":"10.2471\/BLT.16.181636","article-title":"Stroke: a global response is needed","volume":"94","author":"Johnson","year":"2016","journal-title":"Bull World Health Organ"},{"issue":"10154","key":"2023081515544560800_bib2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(18)31874-9","article-title":"Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke","volume":"392","author":"Zerna","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"2023081515544560800_bib3","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1097\/HS9.0000000000000570","article-title":"The fibrinolytic system: mysteries and opportunities","volume":"5","author":"Medcalf","year":"2021","journal-title":"HemaSphere"},{"key":"2023081515544560800_bib4","first-page":"27","article-title":"Stroke care equity in rural and remote areas\u2014novel strategies","volume":"5","author":"Walter","year":"2021","journal-title":"Vessel Plus"},{"issue":"4","key":"2023081515544560800_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000514845","article-title":"The \u201cflying intervention team\u201d: a novel stroke care concept for rural areas","volume":"50","author":"Hubert","year":"2021","journal-title":"Cerebrovasc Dis"},{"issue":"24","key":"2023081515544560800_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","author":"National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023081515544560800_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/0972-5229.156468","article-title":"Problems and limitations in thrombolysis of acute stroke patients at a tertiary care center","volume":"19","author":"Gurav","year":"2015","journal-title":"Indian J Crit Care Med"},{"issue":"12","key":"2023081515544560800_bib8","first-page":"1310","article-title":"Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator","volume":"41","author":"Tanswell","year":"1991","journal-title":"Arzneimittelforschung"},{"issue":"7","key":"2023081515544560800_bib9","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood.V73.7.1842.1842","article-title":"Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat","volume":"73","author":"Larsen","year":"1989","journal-title":"Blood"},{"key":"2023081515544560800_bib10","doi-asserted-by":"crossref","first-page":"661955","DOI":"10.3389\/fneur.2021.661955","article-title":"Hemorrhagic transformation in ischemic stroke and the role of inflammation","volume":"12","author":"Spronk","year":"2021","journal-title":"Front Neurol"},{"issue":"8","key":"2023081515544560800_bib11","first-page":"81","article-title":"Hemorrhagic transformation after cerebral infarction: current concepts and challenges","volume":"2","author":"Zhang","year":"2014","journal-title":"Ann Transl Med"},{"issue":"8","key":"2023081515544560800_bib12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/jcbfm.2014.99","article-title":"Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?","volume":"34","author":"Niego","year":"2014","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"2023081515544560800_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fimmu.2019.00591","article-title":"T-PA suppresses the immune response and aggravates neurological deficit in a murine model of ischemic stroke","volume":"10","author":"Draxler","year":"2019","journal-title":"Front Immunol"},{"issue":"5-6","key":"2023081515544560800_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000446160","article-title":"Preventive ceftriaxone in patients with stroke treated with intravenous thrombolysis: post hoc analysis of the preventive antibiotics in stroke study","volume":"42","author":"Vermeij","year":"2016","journal-title":"Cerebrovasc Dis"},{"issue":"10","key":"2023081515544560800_bib15","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/STROKEAHA.110.592535","article-title":"Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action","volume":"41","author":"Bhatia","year":"2010","journal-title":"Stroke"},{"key":"2023081515544560800_bib16","doi-asserted-by":"crossref","first-page":"589628","DOI":"10.3389\/fneur.2020.589628","article-title":"Plasmin generation potential and recanalization in acute ischaemic stroke; an observational cohort study of stroke biobank samples","volume":"11","author":"Lillicrap","year":"2020","journal-title":"Front Neurol"},{"key":"2023081515544560800_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13231-014-0014-y","article-title":"Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke","volume":"7","author":"Tomkins","year":"2015","journal-title":"Exp Transl Stroke Med"},{"issue":"1","key":"2023081515544560800_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.ATV.21.1.142","article-title":"Disaggregation of in\u00a0vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis","volume":"21","author":"Collet","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"2023081515544560800_bib19","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1161\/01.ATV.14.9.1452","article-title":"Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop","volume":"14","author":"Stringer","year":"1994","journal-title":"Arterioscler Thromb"},{"issue":"23","key":"2023081515544560800_bib20","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1161\/01.CIR.99.23.3050","article-title":"Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance","volume":"99","author":"Zhu","year":"1999","journal-title":"Circulation"},{"issue":"11","key":"2023081515544560800_bib21","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/heart.89.11.1358","article-title":"Thrombolysis: newer thrombolytic agents and their role in clinical medicine","volume":"89","author":"Nordt","year":"2003","journal-title":"Heart"},{"issue":"1","key":"2023081515544560800_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12245-021-00399-w","article-title":"Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review","volume":"15","author":"Potla","year":"2022","journal-title":"Int J Emerg Med"},{"issue":"10","key":"2023081515544560800_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"issue":"7","key":"2023081515544560800_bib24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/CIRCRESAHA.114.302514","article-title":"Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets","volume":"114","author":"Wang","year":"2014","journal-title":"Circ Res"},{"issue":"6","key":"2023081515544560800_bib25","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1160\/TH08-12-0816","article-title":"Single-chain antibodies as diagnostic tools and therapeutic agents","volume":"101","author":"Hagemeyer","year":"2009","journal-title":"Thromb Haemost"},{"issue":"37","key":"2023081515544560800_bib26","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.2174\/138161210794519255","article-title":"Targeting the platelet integrin GPIIb\/IIIa","volume":"16","author":"Hagemeyer","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2023081515544560800_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/01.RES.0000232317.84122.0c","article-title":"Conformation-specific blockade of the integrin GPIIb\/IIIa: a novel antiplatelet strategy that selectively targets activated platelets","volume":"99","author":"Schwarz","year":"2006","journal-title":"Circ Res"},{"issue":"1","key":"2023081515544560800_bib28","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/s41598-017-02498-2","article-title":"Development and validation of a high throughput whole blood thrombolysis plate assay","volume":"7","author":"Bonnard","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"2023081515544560800_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00007256-200333030-00005","article-title":"Haematocrit: within-subject and seasonal variation","volume":"33","author":"Thirup","year":"2003","journal-title":"Sports Med"},{"key":"2023081515544560800_bib30","first-page":"50370","article-title":"Photothrombotic ischemia: a minimally invasive and reproducible photochemical cortical lesion model for mouse stroke studies","volume":"76","author":"Labat-gest","year":"2013","journal-title":"J\u00a0Vis Exp"},{"issue":"3","key":"2023081515544560800_bib31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/STROKEAHA.117.019136","article-title":"Acute or delayed systemic administration of human amnion epithelial cells improves outcomes in experimental stroke","volume":"49","author":"Evans","year":"2018","journal-title":"Stroke"},{"issue":"1","key":"2023081515544560800_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/83358","article-title":"The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling","volume":"7","author":"Nicole","year":"2001","journal-title":"Nat Med"},{"issue":"4","key":"2023081515544560800_bib33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1471-4159.2008.05687.x","article-title":"Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function","volume":"107","author":"Samson","year":"2008","journal-title":"J\u00a0Neurochem"},{"issue":"21","key":"2023081515544560800_bib34","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.282.21.2003","article-title":"Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism","volume":"282","author":"Furlan","year":"1999","journal-title":"JAMA"},{"issue":"3","key":"2023081515544560800_bib35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1042\/bj2670647","article-title":"Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase","volume":"267","author":"Krause","year":"1990","journal-title":"Biochem J"},{"issue":"1","key":"2023081515544560800_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-0038-1661128","article-title":"Biological and thrombolytic properties of proenzyme and active forms of human urokinase\u2014II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys","volume":"52","author":"Collen","year":"1984","journal-title":"Thromb Haemost"},{"issue":"25","key":"2023081515544560800_bib37","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1182\/blood-2010-01-261610","article-title":"Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation","volume":"115","author":"Zaitsev","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2023081515544560800_bib38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MOH.0b013e32833e7561","article-title":"Novel clearance mechanisms of platelets","volume":"17","author":"Grozovsky","year":"2010","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"2023081515544560800_bib39","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2019000782","article-title":"A\u00a0murine photothrombotic stroke model with an increased fibrin content and improved responses to tPA-lytic treatment","volume":"4","author":"Sun","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2023081515544560800_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5811\/westjem.2020.1.45279","article-title":"Using tenecteplase for acute ischemic stroke: What is the hold up?","volume":"21","author":"Zitek","year":"2020","journal-title":"West J Emerg Med"},{"issue":"13","key":"2023081515544560800_bib41","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jama.2020.1511","article-title":"Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK Part 2 randomized clinical trial","volume":"323","author":"Campbell","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"2023081515544560800_bib42","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1161\/STROKEAHA.120.029666","article-title":"Cost-effectiveness of tenecteplase before thrombectomy for ischemic stroke","volume":"51","author":"Gao","year":"2020","journal-title":"Stroke"},{"issue":"10","key":"2023081515544560800_bib43","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1161\/01.CIR.92.10.3032","article-title":"New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA","volume":"92","author":"Benedict","year":"1995","journal-title":"Circulation"},{"issue":"7","key":"2023081515544560800_bib44","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1177\/0271678X16670922","article-title":"Stroke-induced blood-brain barrier breakdown along the vascular tree\u2014no preferential affection of arteries in different animal models and in humans","volume":"37","author":"Krueger","year":"2017","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"issue":"9","key":"2023081515544560800_bib45","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/01.STR.0000137607.61697.77","article-title":"Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis","volume":"35","author":"Audebert","year":"2004","journal-title":"Stroke"},{"issue":"5","key":"2023081515544560800_bib46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5607\/en.2016.25.5.241","article-title":"Inflammation after ischemic stroke: The role of leukocytes and glial cells","volume":"25","author":"Kim","year":"2016","journal-title":"Exp Neurobiol"},{"issue":"2","key":"2023081515544560800_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.12233","article-title":"White blood cell count is an independent predictor of outcomes after acute ischaemic stroke","volume":"21","author":"Furlan","year":"2014","journal-title":"Eur J Neurol"},{"issue":"5","key":"2023081515544560800_bib48","doi-asserted-by":"crossref","first-page":"e0232497","DOI":"10.1371\/journal.pone.0232497","article-title":"Post-stroke infections associated with spleen volume reduction: a pilot study","volume":"15","author":"Nous","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"2023081515544560800_bib49","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1161\/01.STR.0000131658.80951.c3","article-title":"Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation","volume":"35","author":"Yip","year":"2004","journal-title":"Stroke"},{"issue":"6 suppl 1","key":"2023081515544560800_bib50","first-page":"S84","article-title":"Angiophagy: mechanism of microvascular recanalization independent of the fibrinolytic system","volume":"44","author":"Grutzendler","year":"2013","journal-title":"Stroke"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/561\/2071518\/blooda_adv-2021-006691-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/561\/2071518\/blooda_adv-2021-006691-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T20:58:18Z","timestamp":1700513898000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/4\/561\/485108\/Platelet-targeted-thrombolysis-for-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006691","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}